- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05130047
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
A Randomized, Double-Blind, Placebo Controlled Trial of Aldafermin (NGM282) for Treatment of Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 to 75 years, inclusive at Visit 1 Screen.
- Clinical diagnosis of functional diarrhea or IBS with diarrhea according to Rome III or IV criteria at Visit 1 Screen.
Clinical laboratory evidence of BAM (20-22), with at least one of the following results recorded in their past medical history:
- Serum C4 ≥ 52 ng/mL
- Fecal BA > 2337 µmoles / 48 hours
- Total fecal BA > 1000 µmoles / 48 hours + 4 % primary BA
- Fecal primary BA > 10% / 48 hours
- Body mass index (BMI) 18.0 to 45.0 kg/m2, inclusive at Visit 1 Screen
- Understands the study procedures, is willing and able to comply with the study procedures, and is able to give informed consent
If treated with any of the following medications, dosing must be stable for 30 days prior to Visit 1 Screen. Patient must agree to maintain the same dose of medication throughout the study:
- Tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs).
- Bile acid sequestrants such as colestipol, cholestyramine and colesevelam.
- Participants must use one highly effective method of contraception for 30 days before the study through 90 days after study completion for males and through 30 days after study completion for females. Highly effective methods of contraception include: Oral, implantable, transdermal or injectable hormonal contraceptives; standard intrauterine device or vaginal ring; Male or female condoms and diaphragms used with spermicide; abstinence from heterosexual intercourse; female partners exclusively sexually active with a surgically sterilized male partner. Females who are surgically sterile having experienced a prior hysterectomy, bilateral salpingectomy, or bilateral oophorectomy or postmenopausal (defined as12 consecutive months with no menses) are not considered to be of childbearing potential.
Exclusion Criteria:
- Pregnant or lactating
- Structural or metabolic diseases/conditions that affect the gastrointestinal system
Use of the following medications at least 14 days prior to Visit 1 throughout the duration of the treatment period
- Patients may elect to withdraw from bile acid sequestrants such as colestipol, cholestyramine and colesevelam or they may continue but they must continue at the same dose throughout the study.
- GI medications including:
- Anti-nausea agents including trimethobenzamide, promethazine, prochlorperazine, dimenhydrinate, hydroxyzine
- Osmotic laxative agents including lactulose, sorbitol or PEG solutions as Miralax and Glycolax
- Prokinetic agents including tegaserod, metoclopramide, prucalopride, domperidone, erythromycin, clarithromycin and azithromycin.
- 5-HT3 antagonists including alosetron, ondansetron, tropisetron
- Drugs with a known pharmacological activity at 5-HT4, 5-HT2b or 5-HT3 receptors including tegaserod, ondansetron, granisetron and tropisetron
- All narcotics including codeine, morphine, and propoxyphene, either alone or in combination
- Anti-cholinergics including dicyclomine, hyoscyamine, propantheline.
- Antimuscarinics
- Tramadol
- Peppermint oil
- Systemic antibiotics and antibiotics directed at colonic flora including rifaximin and metronidazole
- Use of CNS stimulant medications, including methylphenidate, atomoxetine, modafinil, amphetamines or phentermine.
- Clinically relevant changes in dietary, lifestyle, or exercise regimen within 30 days prior to Visit 1 Screen and throughout the duration of the study
- Any colonic or major abdominal surgery including bariatric surgery, gastric banding, stomach surgery and intestinal or colonic surgery. Procedures such as appendectomy, cholecystectomy, hysterectomy, caesarean section, or polypectomy are allowed as long as they have occurred at least 3 months prior to Visit 1 Screen.
- .History of colorectal cancer, inflammatory bowel disease, diverticulitis, ischemic colitis, microscopic colitis or celiac disease
- History of organic abnormalities of the GI tract, intestinal obstruction, stricture, toxic megacolon, GI perforation, or impaired intestinal circulation.
- Other GI diseases such as GI bleeding or ulcerations
- History of cerebrovascular disease including stroke, TIA, acute coronary syndrome, myocardial infarction or unstable angina
Clinically significant cardiac history or presence of electrocardiogram (ECG) findings at Visit 1 Screen:
- Abnormal heart rate < 40 or > 100 beats per minute
- QTc interval > 470 milliseconds (ms)
- QRS interval ≥ 110 ms
- PR interval ≥ 220 ms
- Hepatic dysfunction including abnormal serum alanine aminotransferase [ALT] or aspartate transaminase [AST] > 3 × upper limit of normal [ULN]); total direct bilirubin > 2 × ULN, or alkaline phosphatase > 2 × ULN at Visit 1 Screen
- Clinically significant renal insufficiency including serum creatinine > 2.5 mg/dL at Visit 1 Screen
- History of severe head injury or history of seizures
- History of suicide attempt or a hospitalization for a major psychiatric condition within 1 year prior to Visit 1 Screen. At Visit 1 Screen or during the optional remote consent and eligibility review, participants will complete the Hospital Anxiety and Depression questionnaire. If either score for anxiety or depression individually exceeds 8, the score will be discussed. The patient will be and advised whether to participate or whether to see their primary care physician.
- History of alcohol use disorder or substance use disorder within 2 years of Visit 1 Screen.
- Significant history or clinical manifestation of any endocrine, allergic, dermatological, hepatic, renal, hematological, pulmonary, GI, neurological or psychiatric disorder, malignancy (with the exception of treated basal cell carcinomas), or any other condition that would prevent the individual from participating in the study due to risk to the scientific validity of study assessments or to personal well-being of the patient.
- Participated in another clinical study that includes an investigational drug or a biologic therapy within 30 days or 5 half-lives, whichever time period is longer, prior to Visit 1 Screen.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aldafermin (NGM282)
Aldafermin (NGM282) is an investigational medication.
It is an engineered analog of FGF-19 which reduces synthesis of bile acids and diarrhea caused by elevated bile acids.
Participants receive aldafermin (NGM282) 1 mg given by subcutaneous injection once daily for 28 days.
|
1 mg solution
Other Names:
|
Placebo Comparator: Placebo
A placebo looks exactly like the study drug but contains no active ingredients.
It is used to learn if the effects seen are truly from the study drug.
Participants receive placebo solution matching aldafermin (NGM282) given by subcutaneous injection once daily for 28 days.
|
Aldafermin placebo solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting Serum C4 Levels
Time Frame: 28 days
|
Fasting serum C4 is measured by liquid chromatography-mass spectrometry.
|
28 days
|
Change in Stool Consistency From Baseline to Day 28
Time Frame: Baseline, 28 days
|
Stool consistency as reported by the patient in daily bowel pattern diaries.
Stool consistency is based on Bristol Stool Form Scale (BSFS) 1: Hard lumps; 2:Lumpy sausage; 3: Cracked sausage; 4: Smooth sausage; 5: Soft lumps; 6: Mushy; 7: Watery.
spectrometry.
|
Baseline, 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stool Consistency
Time Frame: 14 days, 28 days
|
Stool consistency as reported by the patient in daily bowel pattern diaries.
Stool consistency is based on Bristol Stool Form Scale (BSFS) 1: Hard lumps; 2:Lumpy sausage; 3: Cracked sausage; 4: Smooth sausage; 5: Soft lumps; 6: Mushy; 7: Watery.
|
14 days, 28 days
|
Abdominal Pain Score
Time Frame: baseline, 28 days
|
Abdominal pain rated by patient using an 11-point scale, 0 to 10 inclusive with 0 as none and 10 as worst imaginable abdominal pain.
|
baseline, 28 days
|
Bowel Movements
Time Frame: baseline, 28 days
|
The total number of bowel movements per day reported by the participant in the daily bowel pattern diary.
|
baseline, 28 days
|
Proportion of Fecal Secretory (CDCA + DCA) Bile Acid as Measured in a Random Stool Sample by a Validated Laboratory Assay.
Time Frame: Baseline, 14 days, 28 days
|
Fecal secretory bile acids are expressed as a percentage of the total bile acids as measured by high performance liquid chromatography-mass spectrometry.
|
Baseline, 14 days, 28 days
|
Proportion of Fecal Primary (CDCA + CA) Bile Acid as Measured in a Random Stool Sample by a Validated Laboratory Assay.
Time Frame: Baseline,14 days, 28 days
|
Fecal primary bile acids are expressed as a percentage of the total bile acids as measured by high performance liquid chromatography-mass spectrometry.
|
Baseline,14 days, 28 days
|
Total Fecal Bile Acid Concentration in a Random Stool Sample as Measured by a Validated Laboratory Assay.
Time Frame: baseline,14 days, 28 days
|
Total fecal bile acids concentration in micromoles of bile acid per gram stool as measured by high performance liquid chromatography-mass spectrometry.
|
baseline,14 days, 28 days
|
Total Aldafermin Concentration in Serum as Measured by a Validated Laboratory Assay
Time Frame: baseline, 14 days, 28 days
|
Validated aldafermin concentration (PK) laboratory assay
|
baseline, 14 days, 28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Camilleri, M.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-009348
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome With Diarrhea
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
CinPhloro Pharma, LLCRecruitingIrritable Bowel Syndrome With DiarrheaUnited States
-
Sahlgrenska University Hospital, SwedenBeneo-Institute; Atmo Biosciences Pty LtdRecruitingIrritable Bowel Syndrome With DiarrheaSweden
-
Bahria UniversityCompletedIrritable Bowel Syndrome With DiarrheaPakistan
-
Vedic Lifesciences Pvt. Ltd.CompletedIrritable Bowel Syndrome With DiarrheaIndia
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingIrritable Bowel Syndrome With DiarrheaRussian Federation
Clinical Trials on Aldafermin
-
NGM Biopharmaceuticals, IncCompletedImpaired Hepatic FunctionUnited States
-
NGM Biopharmaceuticals, IncCompletedImpaired Renal FunctionUnited States
-
NGM Biopharmaceuticals, IncCompletedNonalcoholic Steatohepatitis | Compensated CirrhosisUnited States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
-
NGM Biopharmaceuticals, IncCompletedHealthy MaleUnited States